[Fluorescence diagnosis of non-melanoma skin cancer].
Photodynamic therapy involves - in dermatological practice usually exogenous - application of a photosensitizer then activation of accumulated protoporphyrin IX by light with an appropriate wavelength after a short incubation period. It is an evidence based method to treat certain non-melanoma skin cancers. During treatment when the excited protoporphyrin IX returns to base state, reactive oxygen species are formed leading to cell death in rapidly proliferating cells. Fluorescence of excited protoporphyrin IX can be used in diagnostics as well. In ultraviolet light, the photodamaged or neoplastic areas show coral red fluorescence which can clearly be distinguished from the much lower fluorescence of adjacent normal tissue. This process is suitable for exact determination of tumor margins so it can be used for planning surgical procedures or after photodynamic therapy at a follow up visit for the visualization of the therapeutic result. The present article reviews the literature of photodynamic diagnosis that is also used by the authors.
Szegedi Tudományegyetem, Általános Orvostudományi Kar Bőrgyógyászati és Allergológiai Klinika Szeged Korányi. gaalmagdolna@yahoo.com
Magdolna
M
Gaál
Róbert
R
Kui
Zsolt
Z
Hunyadi
Lajos
L
Kemény
Rolland
R
Gyulai
D000622:Aminolevulinic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives; D017209:Apoptosis; D002280:Basal Cell Carcinoma / Q000175:diagnosis* / Q000188:drug therapy; D002281:Carcinoma, Basosquamous / Q000175:diagnosis* / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000175:diagnosis* / Q000188:drug therapy; D049109:Cell Proliferation; D003080:Cold Temperature; D005453:Fluorescence; D006801:Humans; D015580:Mohs Surgery / Q000379:methods*; D010146:Pain / Q000209:etiology / Q000517:prevention & control; D010778:Photochemotherapy / Q000009:adverse effects / Q000379:methods*; D017319:Photosensitizing Agents / Q000008:administration & dosage*; D011524:Protoporphyrins / Q000008:administration & dosage*; D017382:Reactive Oxygen Species / Q000378:metabolism; D012878:Skin Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D016896:Treatment Outcome
D017319:Photosensitizing Agents; D011524:Protoporphyrins; D017382:Reactive Oxygen Species; C114767:delta-aminolevulinic acid methyl ester; D000622:Aminolevulinic Acid; C028025:protoporphyrin IX